New Developments in Active Surveillance for Prostate Cancer

Video

In this peer-to-peer discussion, Dr. Loeb and Dr. Choyke discuss new developments in active surveillance for prostate cancer.

At the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 3–7 in Chicago, Stacy Loeb, MD, of the NYU Langone Medical Center in New York, New York, and Peter L. Choyke, MD, of the National Cancer Institute in Bethesda, Maryland, gave presentations during the education session “Contemporary Active Surveillance for Prostate Cancer: Do We Need Better Imaging and Molecular Testing?”

In this peer-to-peer discussion, Dr. Loeb and Dr. Choyke discuss some of the salient points from their session, including the use of magnetic resonance imaging for patient selection and follow-up and the use of new molecular markers that could signal tumor changes in patients on surveillance.

Recent Videos
Ablative technology may generate an immune response that can be enhanced via injected immunotherapy in patients with solid tumors.
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Findings from a phase 1 study may inform future trial designs intended to yield longer responses with PSCA-targeted CAR T cells.
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
Jorge E. Cortes, MD, emphasizes proper communication between patients with chronic myeloid leukemia and their providers during the treatment course.
Related Content